In a new retrospective study published in JAMA Internal Medicine, the researchers have revealed that the patients who were given drugs other than metformin as the first-line therapy for type 2 diabetes are more likely to need to add a second drug later. Analyzing the data of 15,516 patients, the researchers have found that 58% were started with metformin, while the remaining were started with other hypoglycemic agents. However, the study did not include GLP1 receptor agonists in the results even though it was available during the period of the analysis. Nevertheless, strong evidence supports using metformin as the first-line agent. What are your thoughts about this study? What do you think are the other factors that lead to add-on treatment?
To read more, please visit Medpage Today.
Image courtesy of [antpkr] / FreeDigitalPhotos.net